托吡酯与纳曲酮治疗酒精使用障碍:基因分型分层双盲随机对照试验方案(TOP研究)
TOP研究是一项基因分型分层的双盲随机对照试验,计划纳入180例酒精依赖患者,随机接受12周托吡酯(滴定至200 mg/天)或纳曲酮(50 mg/天)治疗,按GRIK1 rs2832407和OPRM1 rs1799971分层,主要结局为每周重度饮酒天数,旨在评估两种药物疗效与成本效果及基因变异对治疗反应的调节作用。
要点
- 托吡酯与纳曲酮均为酒精使用障碍的治疗选择,但疗效存在个体差异。
- 研究按GRIK1 rs2832407和OPRM1 rs1799971基因型分层,探索基因生物标志物指导用药选择。
- 主要结局为每周重度饮酒天数,次要结局包括复发时间、戒断天数比例及BMI、烟草使用、焦虑抑郁症状。
核心结论
- TOP研究旨在评估托吡酯与纳曲酮在酒精依赖患者中的疗效和成本效果,并探讨基因变异对治疗反应的调节作用。
研究设计与样本
- 双盲随机对照试验,计划随机180例酒精依赖参与者,按GRIK1 rs2832407和OPRM1 rs1799971两种多态性分层。
- 干预为12周托吡酯(剂量滴定至200 mg/天)或纳曲酮(50 mg/天),所有参与者接受医疗管理。
主要发现
- 原文未报告研究结果,仅描述研究方案。
关键数值与推荐
- 主要饮酒结局为每周重度饮酒天数;次要饮酒结局包括复发时间、 lapse时间(即首次饮酒时间)和戒断天数百分比。
- 其他次要结局包括体重指数、烟草使用、焦虑症状和抑郁症状。
临床怎么用
- 若研究成功,将为使用基因生物标志物指导酒精依赖的藥物选择提供支持,改善管理策略。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current treatments for alcohol use disorders have limited efficacy and there is a high degree of variability in treatment response. In a randomised, placebo-controlled clinical trial, there was a large effect size for topiramate in people homozygous for the GRIK1 rs2832407*C allele. The primary aim of the TOP study is to examine prospectively the therapeutic and cost-effectiveness of topiramate versus an active control (naltrexone) in improving treatment outcomes for alcohol dependence. Participants will be stratified on rs2832407 to compare C-allele homozygotes with A-allele carriers to examine the moderating effect of rs2832407 on drinking outcomes. An exploratory aim is to examine the moderating effects of rs1799971, a polymorphism in OPRM1, on the response to naltrexone by comparing Asn40 homozygotes with Asp40 carriers. METHODS/DESIGN: This double-blind trial will randomise 180 alcohol-dependent participants to a 12-week regime of either topiramate (titrating the dose up to 200 mg/day) or naltrexone (50 mg/day). Participants will be stratified on the two polymorphisms before randomisation. All participants will receive medical management. The primary drinking outcome will be the number of heavy drinking days per week and secondary drinking outcomes will include the time to relapse, the time to lapse and the percentage of abstinent days. Other secondary outcomes will include body mass index, tobacco use, anxiety symptoms and depressive symptoms. DISCUSSION: If successful, the TOP study will improve management strategies for alcohol dependence by providing support for the use of genetic biomarkers to inform medication selection. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03479086 . Registered on 27 March 2018.
引用
- Morley KC, Kranzler HR, Luquin N, et al. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials. 2018. PMID: 30115121. doi:10.1186/s13063-018-2824-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。